多omics分析揭示了从轻度认知障碍到阿尔茨海默病的进展过程中的两个不同的轨迹
Xiayao Guo1, Hongwen Fu1, Ming Qin1
1State Key Laboratory of Digital Medical Engineering, Southeast University, Nanjing, China.
Journal of Alzheimer's disease : JAD
|August 7, 2025
概括
从轻度认知障碍 (MCI) 开始的阿尔茨海默病进展显示了两种不同的亚型:一种是代谢问题和更慢的衰退,另一种是免疫激活和更快的衰退. 这种多omics方法揭示了个性化阿尔茨海默氏症治疗的关键差异.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 代谢学 代谢学 代谢学
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的异质性,特别是在轻度认知障碍 (MCI) 阶段.
- 对不同MCI进展轨迹的分子驱动因素的不完全理解阻碍了个性化干预.
研究的目的:
- 整合多omics数据 (转录基因组,表观基因组,代谢基因组) 识别不同的MCI-AD进展轨迹.
- 探索潜在的分子机制和驱动这些独特的进展途径的异质性.
主要方法:
- 整合了来自MCI患者的转录组,表观组和代谢组数据.
- 根据进展轨迹将患者分为分层的亚型.
- 通过免疫细胞透,WGCNA和GO/KEGG分析分析了分子差异,免疫微环境和调节途径.
- 开发了使用考克斯回归和随机森林方法的预测模型.
主要成果:
- 确定了两种不同的MCI-to-AD进展亚型:亚型1 (代谢失调,较慢的衰退) 和亚型2 (免疫激活,较快的衰退).
- 轨迹分层揭示了传统方法错过的分子扰动.
- 预后模型准确地预测了1-5年的疾病进展 (AUROC 0.851-0.927).
结论:
- 多omics轨迹分层对于理解阿尔茨海默病异质性至关重要.
- 鉴定出的明显的进展轨迹为AD的潜在机制提供了洞察力.
- 这种方法可以为阿尔茨海默病的个性化治疗策略的开发提供信息.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.3K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
